TC Biopharm (Holdings) Plc (TCBP)
Market Cap | 3.93M |
Revenue (ttm) | 2.41M |
Net Income (ttm) | -16.56M |
Shares Out | 794.95K |
EPS (ttm) | -0.85 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 70,276 |
Open | 5.00 |
Previous Close | 4.97 |
Day's Range | 4.91 - 5.04 |
52-Week Range | 2.81 - 175.00 |
Beta | n/a |
Analysts | Buy |
Price Target | 255.00 (+5,069.27%) |
Earnings Date | n/a |
About TCBP
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. [Read more]
Financial Performance
In 2021, TCBP's revenue was 1.98 million, a change of 0.00% compared to the previous year's 1.98 million. Losses were -13.58 million, 148.7% more than in 2020.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for TCBP stock is "Buy." The 12-month stock price forecast is $255.0, which is an increase of 5,069.27% from the latest price.
News

TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division
Will oversee expansion of U.S. FDA Clinical Tria ls EDINBURGH, Scotland , Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a cl...

TC BioPharm to Host Shareholder Update Call
Conference Call to be held on Monday, February 20 th, 2023 at 10:00 am ET EDINBURGH, Scotland , Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP)...

TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)
EDINBURGH, Scotland , Jan. 19, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), has received written notification from the listing quali...

TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings EDINBURGH, Scotland , Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Compan...

TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update
Dosed first three patients within Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML). Complete and near complete responses (m...

TC BioPharm Announces Closing of $7.35 Million Private Placement
EDINBURGH, Scotland , Nov. 30, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company developing platfo...

TC BioPharm Announces $7.35 Million Private Placement
EDINBURGH, Scotland , Nov. 28, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company developing platfo...

TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia
3 Patients Dosed in 5 Patient Safety Cohort EDINBURGH, Scotland , Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical s...

TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise
SAB selected to advance new therapeutic trials and strategic partnerships EDINBURGH, Scotland , Oct. 26, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP)...

TC BioPharm to Present at Upcoming Investor Conferences
EDINBURGH, Scotland , Oct. 3, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®
EDINBURGH, Scotland , Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
EDINBURGH, Scotland , Aug. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfo...

TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit
Event Taking Place in Boston on July 26-28, 2022 EDINBURGH, Scotland , July 25, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clini...

TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"
Management will Participate in Fireside Chat on TC BioPharm's Journey as a Successful CGT Startup on July 13, 2022 EDINBURGH, Scotland., July 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Bi...

TC Biopharm Announces Closing of $4 Million Underwritten Public Offering
EDINBURGH, Scotland , June 7, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering
EDINBURGH, Scotland , June 2, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally
EDINBURGH, Scotland , May 31, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market
Sector is Expected to Surpass $4 Billion by 2028 Report Highlights Promising Therapy and Rising Investment from Pharmaceutical Companies EDINBURGH, Scotland , May 23, 2022 /PRNewswire/ -- TC Biopharm ...

TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts
Dr. Mark Bonyhadi to spearhead SAB EDINBURGH, Scotland, May 18, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotec...

TC BioPharm Invited to Present at LD Micro Conference
EDINBURGH, Scotland , May 3, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform...

TC BioPharm to Participate in Upcoming Conferences
EDINBURGH, Scotland , April 26, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day
EDINBURGH, Scotland , April 21, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process
6-month shelf-life milestone achieved Successful thaw of highly activated Gamma delta cells EDINBURGH, Scotland , April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Compan...

TC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" Recommendation
EDINBURGH, Scotland , March 29, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Treatment of Acute Myeloid Leukemia
Trial enrollment expected to begin during the first half of 2022 EDINBURGH, Scotland , March 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ...